Over six million Americans live with Alzheimer's. It's the seventh leading cause of death and one-in-nine people suffer from it past the age of 65.
The good news is that, after 20 years of no breakthroughs with this disease, giant advances were made in the last two years.
The biggest breakthrough was announced just this week...
Researchers recently conducted a global trial involving 1,736 people aged 60 to 85 with early-stage Alzheimer's. Half the participants received a placebo; half received monthly infusions of a drug called Donanemab over 18 months.
The result was promising: treatment slowed cognitive decline by 35%. For context, a drug named Lecanemab made headlines last year by achieving 27% - the hope is this number will now continue to rise each year.
"This is a turning point...the first step towards a future where Alzheimer’s is considered a long-term condition alongside diabetes or asthma," the Alzheimer's Society heralds.
"People may have to live with it, but they could have treatments that allow them to effectively manage their symptoms and continue to live fulfilled lives."
What a wild difference a few years makes - let's hope the remarkable progress continues.
|